Mapping Advances Made in the Realm of Prostate Cancer

John Shen, MD, discusses unique features associated with the use of the prostate-specific membrane antigen–directed antibody-drug conjugate ARX517 in patients with metastatic castration-resistant prostate cancer and highlights early efficacy and safety findings with this agent.

ARX517 displayed preliminary efficacy and a strong safety profile in patients with metastatic castration-resistant prostate cancer, according to findings from the phase 1/2 APEX-01 study.

Russell Pachynski, MD, discusses the ongoing investigation of ARX517 in patients with advanced solid tumors in the phase 1/2 APEX-01 trial.